GSK-971086

GSK-971086
Clinical data
Drug class	Selective androgen receptor modulator
Identifiers
	IUPAC name 2-methyl-4-(trifluoromethyl)-1-[[5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]indole-5-carbonitrile;
CAS Number	1018971-95-3;
PubChem CID	86620664;
UNII	8TFL50092H;
Chemical and physical data
Formula	C21H12F6N4O
Molar mass	450.344 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC2=C(N1CC3=NOC(=N3)C4=CC(=CC=C4)C(F)(F)F)C=CC(=C2C(F)(F)F)C#N;
	InChI InChI=InChI=1S/C21H12F6N4O/c1-11-7-15-16(6-5-13(9-28)18(15)21(25,26)27)31(11)10-17-29-19(32-30-17)12-3-2-4-14(8-12)20(22,23)24/h2-8H,10H2,1H3; Key:ZEDODTZELVBHTG-UHFFFAOYSA-N;

GSK-971086 is an investigational new drug that is a selective androgen receptor modulator (SARM) that was being developed by GlaxoSmithKline (GSK) for the potential treatment of sarcopenia.^[1]^[2] As a SARM, GSK-971086 was designed to target androgen receptors in specific tissues, potentially offering therapeutic benefits for muscle wasting conditions while minimizing unwanted androgenic side effects. The compound underwent early-stage clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile in human subjects.^[3]

References

^ "GSK 971086". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 2024-01-14. Retrieved 2024-01-14.
^ Fonseca GW, Dworatzek E, Ebner N, Von Haehling S (August 2020). "Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials". Expert Opinion on Investigational Drugs. 29 (8): 881–891. doi:10.1080/13543784.2020.1777275. PMID 32476495.
^ "Study to Test Safety, Tolerability and Blood Levels of GSK971086 after 1 Dose & 7 Days of Dosing in Healthy Adult Males". GSK Study Register. SAR109935.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.